Kevin Yuen, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1528249661
Payments from drug & device makers
Across 590 payments — averaging $1242.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$153K
- Novo Nordisk$152K
- Ascendis Pharma Endocrinology Inc$132K
- Amryt Pharma Holdings Ltd$49K
- Novo Nordisk AS$40K
- Novo Nordisk Health Care AG$35K
- plus $173K from 19 others
Across 13 payments — averaging $1436.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
- Recordati_rare_diseases_inc.$9K
- Corcept Therapeutics$502
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 135 | $152,962 |
| Novo Nordisk | 144 | $152,245 |
| Ascendis Pharma Endocrinology Inc | 60 | $131,710 |
| Amryt Pharma Holdings Ltd | 30 | $48,887 |
| Novo Nordisk AS | 58 | $39,715 |
| Novo Nordisk Health Care AG | 24 | $34,674 |
| Chiasma, Inc. | 12 | $32,170 |
| Neurocrine Biosciences, Inc. | 32 | $28,999 |
| Recordati_rare_diseases_inc. | 17 | $25,795 |
| Chiesi USA, Inc. | 17 | $22,976 |
| Pfizer(2 entities) | 24 | $19,749 |
| Xeris Pharmaceuticals, Inc. | 15 | $13,291 |
| Sandoz | 1 | $11,780 |
| Novartis | 4 | $10,662 |
| Ipsen Biopharmaceuticals, Inc | 3 | $3,690 |
| Biomarin Pharmaceutical Inc. | 1 | $2,457 |
| Theratechnologies Inc. | 1 | $750 |
| Hexal AG | 1 | $455 |
| AstraZeneca | 1 | $104 |
| EUSA Pharma (US) LLC | 2 | $91 |
| Radius Health, Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $35 |
| Esteve Pharmaceuticals LLC | 1 | $29 |
| Amgen | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $6 |
How this compares
$733,292 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Phoenix
- Joan BaileyPhoenix$316K
- Peter ReavenPhoenix$142K
- Sherman HarmanPhoenix$47K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- Richard ArakakiPhoenix$20K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
- Philip LevyPhoenix$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.